X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Macomics will identify and characterise antibody candidates against the novel target of interest using its ENIGMACTM macrophage drug discovery platform.
Lead Product(s): Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ono Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 23, 2023
Details:
Macomics is developing precision medicines to modulate macrophages for the treatment of cancer. It is progressing a diversified portfolio of therapies targeting disease-specific tumour-associated macrophages (‘TAMs’) towards the clinic.
Lead Product(s): Macrophage-based Therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Caribou Property Limited
Deal Size: $5.8 million Upfront Cash: Undisclosed
Deal Type: Financing July 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
